Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12567462 | 0.97 | ENPP1 (0.33) | ENPP1NOTUMNFE2L2CNR1CNR2 | |
| SCHEMBL12546808 | 0.85 | ESR1 (0.39) | ENPP1TDP1 | |
| SCHEMBL13496248 | 0.84 | ESR1 (0.39) | ENPP1CNR1CNR2TDP1 | |
| SCHEMBL24211024 | 0.83 | NOTUM (0.42) | ENPP1NOTUMNFE2L2TAS2R14CNR1 | |
| SCHEMBL12546368 | 0.80 | ENPP1 (0.38) | ENPP1NFE2L2CNR1CNR2IKBKB | |
| SCHEMBL12367186 | 0.79 | ENPP1 (0.38) | ENPP1 | |
| SCHEMBL10005266 | 0.77 | NOTUM (0.35) | ENPP1NOTUMNFE2L2TAS2R14CNR1 | |
| SCHEMBL12546596 | 0.77 | ESR1 (0.35) | ENPP1TDP1 | |
| SCHEMBL12567615 | 0.75 | ESR1 (0.43) | ENPP1CNR1CNR2TDP1 | |
| SCHEMBL13932251 | 0.74 | TDP1 (0.40) | ENPP1CNR1CNR2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288016-B2 | Fused polycyclic compound and organic light-emitting device using the compound | CANON KABUSHIKI KAISHA (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20110127908-A1 | FUSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110127908-A1 | FUSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND | RPS19, RPL19, RNF168 | ENPP1 4630/4885NOTUM 2309/4885NFE2L2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.